John R. Stuelpnagel, Director at 10x Genomics, Inc. (TXG), sold 11,100 shares at $164.88 ($1.9M) on 2021-03-17, disclosed to the SEC on 2021-03-18.
Open-market sale of $1.9M TXG by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $164.88 | 700 | $115K | 6.1% |
| 2 | $165.80 | 800 | $133K | 7.1% |
| 3 | $166.80 | 601 | $100K | 5.3% |
| 4 | $166.80 | 601 | $100K | 5.3% |
| 5 | $167.98 | 920 | $155K | 8.2% |
| 6 | $167.98 | 920 |
| $155K |
| 8.2% |
| 7 | $169.27 | 1,100 | $186K | 9.9% |
| 8 | $170.09 | 813 | $138K | 7.4% |
| 9 | $170.09 | 813 | $138K | 7.4% |
| 10 | $171.27 | 500 | $86K | 4.6% |
| 11 | $172.29 | 1,266 | $218K | 11.6% |
| 12 | $172.29 | 1,266 | $218K | 11.6% |
| 13 | $173.28 | 400 | $69K | 3.7% |
| 14 | $174.50 | 400 | $70K | 3.7% |
| Total | $169.49 avg | 11,100 | $1.9M | 100% |
| Filing → |
| TXG | SELL | 2023-06-07 | $549K | — | Filing → |
| TXG | SELL | 2022-01-04 | $1.5M | — | Filing → |
| TXG | SELL | 2021-12-03 | $756K | — | Filing → |